The Berlin-based research team first had the idea for a new kind of drug against atrial fibrillation more than ten years ago. They have been supported in creating the spin-off and carrying out initial clinical trials by BMBF and private investors.

The US-American manufacturer Proteintech is expanding its portfolio of next generation antibody technology via acquisition. The Munich-based start-up ChromoTek is the market leader in particularly small and versatile antibodies.

The start-up team have managed to impress with their business plan for a diagnostics company. The highly-sensitive diagnostics allow the parallel expression analysis of individual cells and can contribute to tailor-made approaches to therapy.

Allein in Deutschland erleiden jedes Jahr rund 270.000 Menschen einen Schlaganfall. Bei der Therapie-Wahl stehen Ärztinnen und Ärzte unter enormem Druck. Ein Computermodell soll sie unterstützen und passgenaue Entscheidungen ermöglichen.

Just four months after starting to look for a SARS-CoV-2 vaccine, the biotech firm BioNTech and the US Pfizer pharmaceutical group have announced the selection of a highly-promising main candidate and the start of the global phase 2/3 approval trial.